 | • レポートコード：MRC2208A0023 • 出版社/出版日：Transparency Market Research / 2022年6月 • レポート形態：英文、PDF、170ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査資料では、世界の心房細動（AF）市場について広く調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療タイプ別（薬理学的治療、非薬理学的治療、メイズ手術、電気除細動）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などをまとめました。なお、当書に掲載されている企業情報には、Agilent Technologies, Inc.、Allied Healthcare Products, Inc.、CareFusion Corporation、Covidien plc、GE Healthcare Ltd.、GF Health Products, Inc.、Omron Healthcare, Inc.、PARI Respiratory Equipment, Inc.、Philips Healthcareなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の心房細動（AF）市場規模：治療タイプ別（薬理学的治療、非薬理学的治療、メイズ手術、電気除細動） ・世界の心房細動（AF）市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Atrial Fibrillation Market – Scope of Report
TMR’s report on the global atrial fibrillation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global atrial fibrillation market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global atrial fibrillation market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the atrial fibrillation market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global atrial fibrillation market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global atrial fibrillation market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global atrial fibrillation market.
The report delves into the competitive landscape of the global atrial fibrillation market. Key players operating in the global atrial fibrillation market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global atrial fibrillation market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market atrial fibrillation.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Atrial Fibrillation Market
4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Atrial Fibrillation Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Developments
5.2. Disease Prevalence & Incidence Rate, by Region/Globally
5.3. Atrial Fibrillation Overview
5.4. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Atrial Fibrillation Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Pharmacological Treatment
6.3.1.1. Anti-arrhythmic Drugs
6.3.1.2. Anti-coagulant Drugs
6.3.2. Non-pharmacological Treatment
6.3.2.1. Catheter Ablation
6.3.2.1.1. Radiofrequency Based
6.3.2.1.2. Cryoablation Based
6.3.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
6.3.2.1.4. Microwave Based
6.3.2.1.5. Laser Based
6.3.2.2. Maze Surgery
6.3.2.3. Electric Cardioversion
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Atrial Fibrillation Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America Atrial Fibrillation Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Treatment Type, 2017–2031
8.2.1. Pharmacological Treatment
8.2.1.1. Anti-arrhythmic Drugs
8.2.1.2. Anti-coagulant Drugs
8.2.2. Non-pharmacological Treatment
8.2.2.1. Catheter Ablation
8.2.2.1.1. Radiofrequency Based
8.2.2.1.2. Cryoablation Based
8.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
8.2.2.1.4. Microwave Based
8.2.2.1.5. Laser Based
8.2.2.2. Maze Surgery
8.2.2.3. Electric Cardioversion
8.3. Market Value Forecast, by Country, 2017–2031
8.3.1. U.S.
8.3.2. Canada
8.4. Market Attractiveness Analysis
8.4.1. By Treatment Type
8.4.2. By Country
9. Europe Atrial Fibrillation Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2017–2031
9.2.1. Pharmacological Treatment
9.2.1.1. Anti-arrhythmic Drugs
9.2.1.2. Anti-coagulant Drugs
9.2.2. Non-pharmacological Treatment
9.2.2.1. Catheter Ablation
9.2.2.1.1. Radiofrequency Based
9.2.2.1.2. Cryoablation Based
9.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
9.2.2.1.4. Microwave Based
9.2.2.1.5. Laser Based
9.2.2.2. Maze Surgery
9.2.2.3. Electric Cardioversion
9.3. Market Value Forecast, by Country/Sub-region, 2017–2031
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Market Attractiveness Analysis
9.4.1. By Treatment Type
9.4.2. By Country/Sub-region
10. Asia Pacific Atrial Fibrillation Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Pharmacological Treatment
10.2.1.1. Anti-arrhythmic Drugs
10.2.1.2. Anti-coagulant Drugs
10.2.2. Non-pharmacological Treatment
10.2.2.1. Catheter Ablation
10.2.2.1.1. Radiofrequency Based
10.2.2.1.2. Cryoablation Based
10.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
10.2.2.1.4. Microwave Based
10.2.2.1.5. Laser Based
10.2.2.2. Maze Surgery
10.2.2.3. Electric Cardioversion
10.3. Market Value Forecast, by Country/Sub-region, 2017–2031
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia & New Zealand
10.3.5. Rest of Asia Pacific
10.4. Market Attractiveness Analysis
10.4.1. By Treatment Type
10.4.2. By Country/Sub-region
11. Latin America Atrial Fibrillation Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Pharmacological Treatment
11.2.1.1. Anti-arrhythmic Drugs
11.2.1.2. Anti-coagulant Drugs
11.2.2. Non-pharmacological Treatment
11.2.2.1. Catheter Ablation
11.2.2.1.1. Radiofrequency Based
11.2.2.1.2. Cryoablation Based
11.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
11.2.2.1.4. Microwave Based
11.2.2.1.5. Laser Based
11.2.2.2. Maze Surgery
11.2.2.3. Electric Cardioversion
11.3. Market Value Forecast, by Country/Sub-region, 2017–2031
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Market Attractiveness Analysis
11.4.1. By Treatment Type
11.4.2. By Country/Sub-region
12. Middle East & Africa Atrial Fibrillation Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Pharmacological Treatment
12.2.1.1. Anti-arrhythmic Drugs
12.2.1.2. Anti-coagulant Drugs
12.2.2. Non-pharmacological Treatment
12.2.2.1. Catheter Ablation
12.2.2.1.1. Radiofrequency Based
12.2.2.1.2. Cryoablation Based
12.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
12.2.2.1.4. Microwave Based
12.2.2.1.5. Laser Based
12.2.2.2. Maze Surgery
12.2.2.3. Electric Cardioversion
12.3. Market Value Forecast, by Country/Sub-region, 2017–2031
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East & Africa
12.4. Market Attractiveness Analysis
12.4.1. By Treatment Type
12.4.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player – Competition Matrix (by tier and size of companies)
13.2. Company Profiles
13.2.1. Agilent Technologies, Inc.
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Allied Healthcare Products, Inc.
13.2.2.1. Company Overview
13.2.2.2. Business Overview
13.2.2.3. Financial Overview
13.2.2.4. SWOT Analysis
13.2.2.5. Strategic Overview
13.2.3. CareFusion Corporation
13.2.3.1. Company Overview
13.2.3.2. Business Overview
13.2.3.3. Financial Overview
13.2.3.4. SWOT Analysis
13.2.3.5. Strategic Overview
13.2.4. Covidien plc
13.2.4.1. Company Overview
13.2.4.2. Business Overview
13.2.4.3. Financial Overview
13.2.4.4. SWOT Analysis
13.2.4.5. Strategic Overview
13.2.5. GE Healthcare Ltd.
13.2.5.1. Company Overview
13.2.5.2. Business Overview
13.2.5.3. Financial Overview
13.2.5.4. SWOT Analysis
13.2.5.5. Strategic Overview
13.2.6. GF Health Products, Inc.
13.2.6.1. Company Overview
13.2.6.2. Business Overview
13.2.6.3. Financial Overview
13.2.6.4. SWOT Analysis
13.2.6.5. Strategic Overview
13.2.7. Omron Healthcare, Inc.
13.2.7.1. Company Overview
13.2.7.2. Business Overview
13.2.7.3. Financial Overview
13.2.7.4. SWOT Analysis
13.2.7.5. Strategic Overview
13.2.8. PARI Respiratory Equipment, Inc.
13.2.8.1. Company Overview
13.2.8.2. Business Overview
13.2.8.3. Financial Overview
13.2.8.4. SWOT Analysis
13.2.8.5. Strategic Overview
13.2.9. Philips Healthcare
13.2.9.1. Company Overview
13.2.9.2. Business Overview
13.2.9.3. Financial Overview
13.2.9.4. SWOT Analysis
13.2.9.5. Strategic Overview
Table 1: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, 2017–2031
Table 2: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology, 2017–2031
Table 3: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 4: North America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031
Table 5: North America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 6: Europe Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031
Table 7: Europe Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 8: Asia Pacific Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031
Table 9: Asia Pacific Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Latin America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031
Table 11: Latin America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Middle East & Africa Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031
Table 13: Middle East & Africa Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031